Disc Medicine, Inc.
IRONHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeDisc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients. The company carries a $3.31B market cap, placing it firmly in the mid-cap category. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Market Cap
$3.31B
Beta
2.11
P/E (TTM)
—
P/E (Fwd)
-10.77
EPS (TTM)
$-6.58
EPS (Fwd)
$-6.92
ROE
-39.1%
ROA
-24.0%
Cash
$717.7M
Total Debt
$60.9M
Free CF
-$117.5M
52W Change
-16.9%
Annual Financials
Cash vs Debt
Where IRON stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IRON finished 12.08% above its 150-day moving average ($70.42) and 11.70% above its 200-day moving average ($70.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IRON overbought or oversold?
At the October 20, 2026 close, IRON's RSI(14) was 67.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $717.7M in cash comfortably exceeding the $60.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$117.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -39.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Disc Medicine, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, IRON has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Disc Medicine, Inc.'s trajectory.